This proof-of-concept randomized controlled clinical trial explores the safety, feasibility, and preliminary efficacy of psilocybin-enhanced psychotherapy versus treatment-as-usual among military Veterans being treated for methamphetamine use disorder within a residential treatment facility.

This proof-of-concept clinical trial is the first to explore the safety and feasibility of MDMA-assisted psychotherapy conducted in a group therapy format. Participants will be military Veterans with PTSD.

SNaP Lab is a site for this Phase 3, randomized, double-blind, multicenter study to evaluate the efficacy, safety, and tolerability of psilocybin in adults with Major Depressive Disorder (MDD).

Many patients with chronic pelvic pain are not adequately helped by current treatments or may experience side effects. Emerging evidence suggests that psilocybin is effective in difficult-to-treat pain syndromes, such as migraines or cluster headaches. This study aims to assess the safety and feasibility of a single dose of psilocybin with supportive therapy to treat chronic pelvic pain and will be the first to evaluate psilocybin therapy for this condition. 

This proof-of-concept randomized controlled clinical trial evaluates the safety and effectiveness of MDMA-assisted therapy for adults with social anxiety disorder.

OPEN is a nascent practice-based research network, designed to assess the safety and equity of psilocybin services in community-based settings and develop a framework for future studies. The OPEN project aims to collect confidential information from licensed psilocybin facilitators and their clients to assess their experience with legal psilocybin services.